Interview with Per Jansson, CEO of Vicore Pharma

Redeye published an interview with Per Jansson, CEO of Vicore Pharma.

Redeye published an interview with Per Jansson, CEO of Vicore Pharma.

View the interview via  Redeyes homepage .

Nina Carlén, IR, Communication & Administration coordinator
Tel: 0763-90 94 04 eller e-mail:  nina.carlen@vicorepharma.com  

About Vicore Pharma Holding
Vicore Pharma, a Nasdaq Stockholm First North listed holding-, and management company. Vicore Pharma develops drugs targeting stimulation of the AT2 Receptor (AT2R) in the Renin-Angiotensin-System (RAS). The company vision is to establish AT2-agonists as a new effective class of small molecule drugs. Our lead candidate, C21 will be focused on the indication Idiopatic pulmonary fibrosis (IPF). For further information, please refer to www.vicorepharma.com

Vicore Pharmas share is listed on NASDAQ Stockholm, First North under the ticker VICO.  The company´s Certified Adviser is Redeye AB.

Subscribe